Mitochondria are the tiny power plants inside almost every cell in your body, and the idea that hyperbaric oxygen therapy (HBOT) can build more of them, or make the ones you have work harder, is one of the most exciting claims in the longevity and performance world. The pitch sounds simple: flood your tissues with oxygen under pressure, and your cells respond by making fresh mitochondria. This article walks through what "mitochondrial biogenesis" actually means, what the lab and human evidence really shows in 2026, and where the marketing runs ahead of the science.
What Mitochondrial Biogenesis Actually Means
Your cells don't keep a fixed number of mitochondria forever. They grow, divide, get recycled, and get replaced. "Biogenesis" is the formal word for building new mitochondria. When you exercise hard, your muscle cells sense the stress and switch on a set of genes that crank out more mitochondrial machinery. More mitochondria, or better-functioning ones, generally means more energy (ATP) and better endurance.
The master switch for this process has a clunky name: PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha). Think of PGC-1α as the foreman who tells the cell to start construction. It works alongside a sensor protein called SIRT-1 and a downstream factor called TFAM that copies mitochondrial DNA. When researchers want to know whether something truly triggers biogenesis, they look at this PGC-1α/SIRT-1 pathway and at the actual amount of mitochondrial material in the cell.
This distinction matters more than it sounds. A treatment can make existing mitochondria work better (function) without making more of them (biogenesis). Those are two different claims, and HBOT marketing tends to blur them together. Keeping them separate is the key to reading the evidence honestly.
There's a third thing to track, too: mitochondrial quality control. Cells don't just build new mitochondria; they also clear out broken ones through a recycling process called mitophagy, and they fuse and split mitochondria to share resources. Those fusion and fission steps are run by their own proteins (OPA1, MFN1, MFN2, DRP1). A complete "more and better mitochondria" story would need biogenesis (new ones), good function (efficient ones), and healthy turnover (broken ones cleared). When you read an HBOT claim, ask which of these three it's actually about. Most studies only measure one or two.
Why oxygen and pressure might do this at all
HBOT puts you in a sealed chamber and raises the pressure to between 1.3 and 2.4 times normal atmospheric pressure while you breathe oxygen. That dissolves far more oxygen into your blood plasma than breathing room air ever could. Under normal conditions, almost all the oxygen in your blood rides on hemoglobin inside red blood cells. Under pressure, a much larger share dissolves directly into the plasma, so oxygen can reach tissue that blood cells struggle to supply.
The leading theory for why this would touch mitochondria is counterintuitive. You'd think too much oxygen would damage cells, and at high enough doses it does. But the brief, controlled spike in oxygen creates a small amount of oxidative stress, and the cell reacts by ramping up its repair and energy systems. Scientists call this mitohormesis — a little stress that triggers a protective overcompensation. The same logic explains why exercise, which floods muscle with reactive oxygen species, makes you fitter rather than sicker. HBOT is trying to borrow that signal. If you want the deeper physiology, our guide on how HBOT increases tissue oxygenation breaks down the pressure and gas math.
A second proposed mechanism is the "hyperoxic-hypoxic paradox." Some researchers argue that the swings between high oxygen (inside the chamber) and a relative drop afterward mimic the signals of low oxygen, tricking the body into the same adaptive responses you'd get from altitude training or intense exercise. This idea is central to the protocols used by clinics that market HBOT for performance and aging. It's plausible and partly supported, but it is still a hypothesis, not a proven fact, and it's worth naming as such.
The Evidence, Graded Honestly
Here's the short version before the details: the cell and animal data are genuinely interesting and fairly consistent. The human data are thinner, the protocols are all over the place, and one of the best human studies actually failed to find a change in the main biogenesis marker. So the picture is "promising but unproven," not "settled science."
The table below sorts the main studies by what they measured and how strong they are.
| Study (year) | Model | What it measured | Result | Evidence strength |
|---|---|---|---|---|
| HL-1 cardiomyocytes (2025) | Cells in a dish | PGC-1α, ROS, ATP, mitochondrial function | HBOT raised PGC-1α, ROS, oxygen use, and ATP — but worsened function in already-damaged cells | Low (in vitro only) |
| Parkinson's model (2022) | Mice | SIRT-1 / PGC-1α / TFAM, neuron survival | HBOT restored biogenesis signaling and protected neurons | Low-moderate (animal) |
| Middle-aged athletes (2022) | Humans, muscle biopsy | Mitochondrial mass, respiration, PGC-1α | Mass +17%, respiration up — but PGC-1α did not change | Moderate (small RCT) |
| Type 2 diabetes (2023) | Humans | Muscle/fat mitochondrial respiration, ATP | Respiration doubled to tripled, hepatic ATP doubled | Moderate (tiny, single dose) |
| Older adults (2024) | Humans | VO2max, fitness | VO2max/kg rose ~1.9 mL/kg/min | Moderate (RCT, no biopsy) |
Cell studies: clear signal, big asterisks
In a 2025 in-vitro study, researchers exposed heart muscle cells (HL-1 cardiomyocytes) to hyperbaric oxygen. The treatment increased reactive oxygen species, raised PGC-1α, and boosted mitochondrial oxygen consumption, membrane potential, and ATP production. On its face, that's a textbook demonstration of oxygen stress driving biogenesis through the expected pathway. It's the kind of clean, mechanism-confirming result researchers love, because every step of the proposed chain lit up: oxygen stress went up, the biogenesis switch went up, and energy output went up.
But the same paper carries a warning that rarely makes it into clinic brochures. In cells that already had damaged mitochondria, HBOT made function worse, not better. The authors concluded the effect is "context-dependent" and likely runs through "a stress-mediated response." That's an honest finding and a useful one. More oxygen is not automatically more energy. If your mitochondria are already struggling, adding oxidative stress can push them further over the edge instead of toward repair. A dish of cells is also a long way from a living person — there's no blood flow, no hormones, no immune system, none of the context that decides how a real body responds. So this counts as low-strength evidence no matter how clean the result looks.
Animal studies: consistent, but still rodents
The most-cited mechanism paper comes from a 2022 mouse study in Parkinson's disease. A toxin (MPTP) was used to crash the animals' mitochondrial biogenesis signaling — knocking down SIRT-1, PGC-1α, and TFAM and killing dopamine neurons. HBOT pushed those markers back up, increased the number of surviving dopamine-producing neurons, raised the protective growth factor BDNF, and dialed down inflammation and cell-death signaling. It's the clearest published case that HBOT can switch the biogenesis pathway back on through SIRT-1/PGC-1α.
The catch is the usual one for animal work. Mice are not people, the disease was artificially induced, and the doses used in rodents don't map cleanly onto a human clinic protocol. There's also a built-in advantage hiding in the design: the toxin first suppressed biogenesis, so HBOT had a deep hole to climb out of. Restoring a system that was artificially broken is not the same as boosting a healthy one above baseline. A 2024 review of HBOT as a neuromodulation tool grouped this study with other promising-but-early animal work and reached the same verdict — biologically interesting, clinically unproven. This is solid mechanistic support, but it cannot prove the same thing happens in your body.
Human studies: where it gets complicated
The most important human study for this topic is a 2022 randomized controlled trial in middle-aged master athletes. Thirty-one people finished it — 16 got real HBOT (40 daily sessions, 2 ATA, 100% oxygen, 60 minutes each) and 15 got a sham. The researchers took actual muscle biopsies, which is the gold standard for measuring mitochondria directly.
The good news: mitochondrial mass rose about 17% in the HBOT group versus a small drop in the sham group, and maximal oxygen phosphorylation capacity went up. Real, measurable improvements in mitochondrial function and content.
Now the honest part. The same study measured PGC-1α — the master biogenesis switch — and found no significant change (p = 0.699). The two fusion markers (OPA1, p = 0.12; MFN1+2, p = 0.09) also didn't move significantly. So the headline "HBOT triggers mitochondrial biogenesis in humans" is not exactly what this study showed. It showed more mitochondrial mass (a 17% rise versus an 8.5% drop in the sham group, p = 0.0002) and better respiration (effect size 1.085, p = 0.04) without lighting up the classic biogenesis transcription factor. The cells got more mitochondrial material, but the textbook "build new ones" signal wasn't captured. That's a meaningful gap, and you should be skeptical of anyone who cites this study as proof of biogenesis without mentioning the PGC-1α result.
How can mass go up while the biogenesis switch stays flat? A few honest possibilities: the muscle biopsies may have been taken at the wrong time to catch a transient PGC-1α spike (the protein pulses and fades), the small sample (16 vs 15) may have lacked the power to detect a real change, or the extra mitochondrial mass may have come more from reduced breakdown than from new construction. The researchers can't say which, and neither can anyone else. That uncertainty is the point. The result is real and encouraging, but it doesn't cleanly prove the biogenesis mechanism it's so often used to sell.
A 2023 crossover trial in 12 men with type 2 diabetes found striking metabolic numbers: skeletal muscle mitochondrial respiratory control roughly doubled, white adipose tissue respiration roughly tripled, and liver ATP doubled after HBOT, while fasting blood glucose dropped 19% and whole-body insulin sensitivity rose about 11%. Impressive — but read the design. This was a single two-hour exposure, not a 40-session course. A one-time spike in respiration is a functional change, not evidence that the body built new mitochondria over time. The authors themselves framed it as mitohormesis and reduced endoplasmic-reticulum stress, not biogenesis. And with only 12 men, all without serious complications, the result is a strong signal in a tiny, narrow group — not a population-level finding.
A 2024 randomized trial in sedentary older adults (63 people, 60 sessions over 12 weeks at 2 ATA) found a real fitness gain — VO2max per kilogram rose about 1.9 mL/kg/min (p = 0.0034). That's a legitimate performance result, and fitness gains in this age group matter for healthspan. But this trial took no muscle biopsies, so it can't tell us whether the engine of that improvement was new mitochondria, better blood flow, improved heart perfusion, or simply the effect of showing up daily for three months. The authors themselves pointed back to the earlier athlete biopsy data to infer a mitochondrial mechanism, because this study couldn't measure one directly.
Does the pressure level matter?
This is where the consumer market gets messy. The human studies that actually measured mitochondrial mass and respiration used 2 ATA with 100% oxygen — full medical-grade pressure in a hard chamber. That's a meaningfully different exposure from the soft-shell "mild HBOT" (mHBOT) chambers sold for home use, which typically run around 1.3 ATA, often with an oxygen concentrator rather than pure oxygen.
The mitohormesis theory says the size of the oxygen dose drives the size of the adaptive signal. If that's right, a 1.3 ATA chamber delivers a much smaller oxygen spike and would be expected to produce a smaller mitochondrial effect, if any. No published trial has shown mitochondrial mass gains from mild home chambers the way the 2 ATA athlete study did. So the strongest mitochondrial data come from a protocol most home users aren't actually running. Anyone buying a soft chamber on the strength of these studies should know the studies didn't test their setup. The controversy over whether low-pressure chambers do anything biologically is covered in our piece on why 1.3 ATA mild HBOT is controversial.
The number of sessions matters too. The mass-and-respiration gains came after 40 daily sessions over two months. There's no evidence a handful of one-off sessions does anything lasting to mitochondrial content. If the benefit is real, it looks like a dose you have to earn over weeks, not a quick reset.
What the Evidence Does and Doesn't Support
Pulling it together:
- Supported by decent evidence: HBOT can increase mitochondrial content/mass and improve mitochondrial respiration in human muscle after a multi-week protocol. It can also produce measurable fitness gains.
- Supported only in cells and animals: HBOT activates the SIRT-1/PGC-1α biogenesis pathway.
- Not yet shown in humans: A clean, significant rise in PGC-1α (the canonical biogenesis switch) from HBOT. The best human biopsy study specifically did not find it.
- Overstated in marketing: That HBOT reliably "builds new mitochondria" in healthy people for anti-aging. The mass increase is real; the biogenesis-pathway proof in humans is not there yet.
This is exactly the kind of nuance that gets lost in clinic ads. The longevity angle — the idea that more mitochondria slow aging — leans heavily on this biogenesis story. For how that connects to other anti-aging claims, see our breakdown of HBOT for anti-aging and the telomere research and the broader HBOT anti-aging and longevity overview.
How HBOT Compares to Other Ways to Build Mitochondria
If your actual goal is more or better mitochondria, it's worth knowing that HBOT is not the only — or the most proven — path. The table below puts it in context.
| Method | Biogenesis evidence in humans | Cost / access | Notes |
|---|---|---|---|
| Aerobic + interval exercise | Strong, decades of biopsy data | Free | Gold standard for PGC-1α activation |
| Resistance training | Good | Low | Builds mass and metabolic health |
| Cold/heat exposure | Moderate | Low | Sauna and cold both nudge mitohormesis |
| Caloric restriction / fasting | Moderate | Free | Activates SIRT-1/PGC-1α pathway |
| HBOT | Mixed/emerging | High ($200–$450+/session) | Raises mass; PGC-1α effect unproven in humans |
The plain takeaway: structured exercise has overwhelmingly stronger evidence for mitochondrial biogenesis than HBOT does, costs nothing, and works through the exact PGC-1α pathway HBOT is supposed to hit. HBOT may be a useful add-on, especially for people who can't exercise normally, but it is not a shortcut around training. If you're weighing it against other modalities, our comparison of HBOT versus red light therapy covers another popular "cellular energy" claim.
Safety and the Catch With Oxidative Stress
The whole biogenesis theory rests on controlled oxidative stress, and that cuts both ways. A little is a signal; a lot is damage. The 2025 cell study's finding — that HBOT can worsen function in already-damaged mitochondria — is a real-world caution, not a footnote. People with significant cardiac or metabolic disease shouldn't assume "more oxygen = more energy."
Standard HBOT risks still apply and don't change because the goal is mitochondrial. The most common are ear and sinus barotrauma from pressure changes. Less common but more serious are oxygen toxicity (which can cause seizures at high pressures and long exposures), temporary nearsightedness from lens changes, and, rarely, lung issues. Anyone with certain lung conditions, recent ear surgery, or specific chemotherapy histories needs medical clearance first.
There is no FDA-cleared "mitochondrial biogenesis" or "anti-aging" indication for HBOT. The FDA clears HBOT devices for a specific list of conditions — wound healing, decompression sickness, carbon monoxide poisoning, and similar — and everything in this article falls outside that list. That means it's an off-label, cash-pay use with no insurance coverage and no regulatory endorsement of the biogenesis claim.
Who This Might Actually Be For
Given the honest evidence grade, HBOT-for-mitochondria makes the most sense for a narrow group:
- Athletes plateaued on training who want a research-backed (if modest) edge in mitochondrial mass and VO2max, and who can afford a 40-session course.
- People who can't exercise normally due to injury or illness, where the older-adult fitness data is most relevant.
- Patients with specific metabolic dysfunction under medical supervision, where the diabetes data hints at benefit.
It makes the least sense as a standalone anti-aging purchase for a healthy person who isn't already maximizing the free, proven options — sleep, training, and diet. If you're spending thousands chasing mitochondria while skipping interval workouts, the science says you have the priorities backwards.
The Bottom Line
HBOT does something real to human mitochondria — it can raise mitochondrial mass and improve respiration after a multi-week protocol, and it activates the biogenesis pathway in cells and animals. But the cleanest human study failed to show a change in PGC-1α, the actual biogenesis switch, and the most dramatic human numbers came from a single-dose diabetes study that measured function, not new mitochondria. The mechanism is plausible, the early data are encouraging, and the marketing is well ahead of the proof. Treat it as a promising adjunct, not a validated mitochondrial fountain of youth.
Frequently Asked Questions
Does HBOT really create new mitochondria in humans?
Not clearly. In a randomized muscle-biopsy study, HBOT raised mitochondrial mass about 17% but did not significantly change PGC-1α, the master biogenesis switch. So it increased mitochondrial content without proving the classic "build new ones" signal fired. Cell and animal studies do show PGC-1α activation, but that hasn't been confirmed in people yet.
How many HBOT sessions would it take to affect mitochondria?
The human study that measured muscle mitochondrial mass used 40 daily sessions at 2 ATA, 60 minutes each, over about two months. The single-dose diabetes study showed short-term respiration changes after just one two-hour session, but that's a temporary functional shift, not lasting biogenesis. There's no agreed "optimal" protocol for this goal.
Is HBOT better than exercise for building mitochondria?
No. Aerobic and interval exercise have decades of human biopsy evidence for activating PGC-1α and increasing mitochondrial content, and they're free. HBOT is expensive, less proven for biogenesis specifically, and at best an add-on. The science strongly favors training as the primary tool.
Can HBOT ever harm my mitochondria?
Possibly, in the wrong context. A 2025 cell study found HBOT could worsen function in mitochondria that were already damaged, because the treatment works through oxidative stress that overwhelmed unhealthy cells. This is why people with significant heart or metabolic disease should get medical clearance rather than assume more oxygen is always better.
Is mitochondrial biogenesis an FDA-approved use of HBOT?
No. The FDA clears HBOT for conditions like wound healing, decompression sickness, and carbon monoxide poisoning. Mitochondrial biogenesis, anti-aging, and performance are all off-label, cash-pay uses with no insurance coverage and no FDA endorsement of the claim.
This article is for educational purposes only and is not medical advice. Talk to a qualified physician before starting hyperbaric oxygen therapy, especially if you have heart, lung, or metabolic conditions.
Sources
- Effects of HBOT on Mitochondrial Respiration and Physical Performance in Middle-Aged Athletes: A Blinded, Randomized Controlled Trial (PubMed)
- Hyperbaric oxygen rapidly improves tissue-specific insulin sensitivity and mitochondrial capacity in type 2 diabetes: a randomised crossover trial (PubMed)
- Physical enhancement of older adults using hyperbaric oxygen: a randomized controlled trial (PubMed)
- HBOT Improves Parkinson's Disease by Promoting Mitochondrial Biogenesis via the SIRT-1/PGC-1α Pathway (PubMed)
- Hyperbaric oxygen increases mitochondrial biogenesis and function with oxidative stress in HL-1 cardiomyocytes (PubMed)
- Hyperbaric oxygen therapy as a neuromodulatory technique: a review of recent evidence (PubMed)
- PubMed search: hyperbaric oxygen and mitochondrial biogenesis